VEETIDS '125'
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEETIDS '125' (VEETIDS '125').
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
| Metabolism | Hepatic metabolism is minimal; primarily excreted unchanged in urine via renal tubular secretion. |
| Excretion | Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%. |
| Half-life | 2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation. |
| Protein binding | 10-20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.3-0.5 L/kg (total body water), indicating limited tissue penetration except in kidneys and urine. |
| Bioavailability | Oral: 60-80% (variable due to first-pass metabolism); IM: 90-100% (complete). |
| Onset of Action | Oral: 30-60 minutes; IM: 10-20 minutes; IV: immediate (5-10 minutes for therapeutic levels). |
| Duration of Action | Oral/IM: 6-8 hours; IV: 4-6 hours. Clinical note: duration is dose-dependent and prolonged in renal impairment. |
| Molecular Weight | 346.33 |
125 mg orally twice daily for 5-10 days.
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl 30-50 mL/min: 125 mg once daily; CrCl 15-29 mL/min: 125 mg every 48 hours; CrCl <15 mL/min or hemodialysis: 125 mg every 48 hours. |
| Liver impairment | Child-Pugh A: 125 mg once daily; Child-Pugh B: 125 mg every 48 hours; Child-Pugh C: not recommended. |
| Pediatric use | For children ≥1 year: 2.5 mg/kg orally twice daily (max 125 mg/dose). |
| Geriatric use | Start at 125 mg once daily; increase to twice daily if tolerated and renal function adequate (CrCl >50 mL/min). |
| 1st trimester | Avoid use due to teratogenicity (e.g., neural tube defects, cardiac malformations) demonstrated in animal studies and limited human data. |
| 2nd trimester | Use only if benefit outweighs risk; potential fetal toxicity (e.g., impaired growth, ototoxicity). |
| 3rd trimester | Contraindicated in third trimester due to risk of neonatal hemorrhage, kernicterus, and gray baby syndrome. |
Clinical note
Comprehensive clinical and safety monograph for VEETIDS '125' (VEETIDS '125').
| Placental transfer | Readily crosses the placenta with fetal serum levels reaching 50-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts; may cause diarrhea, rash, or sensitization in infants. Use caution in breastfeeding women, especially if infant is jaundiced or has G6PD deficiency. |
■ FDA Black Box Warning
No FDA black box warning identified for penicillin V potassium.
| Serious Effects |
Hypersensitivity to drug or any componentSevere hepatic impairmentPorphyriaConcomitant use with disulfiram or metronidazole (antabuse-like reaction)Third trimester of pregnancyNursing infants with hyperbilirubinemia or G6PD deficiency
| Precautions | Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported, Use with caution in patients with renal impairment, Prolonged use may result in overgrowth of nonsusceptible organisms, Clostridium difficile-associated diarrhea (CDAD) may occur |
| Food/Dietary | Avoid acidic foods and beverages (e.g., citrus fruits, tomatoes, carbonated drinks) within 2 hours of dosing as they may decrease absorption. High-fat meals can delay absorption but do not significantly affect total exposure. No specific dietary restrictions required. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | VEETIDS '125' contains valproate. Valproate is associated with a high risk of congenital malformations (neural tube defects, facial dysmorphism, cardiac defects) if used during the first trimester. Exposure in the second and third trimesters may cause fetal valproate syndrome, neurodevelopmental delays, and decreased IQ. Use is contraindicated in pregnancy unless no alternative. |
| Fetal Monitoring | Maternal: Plasma valproate levels, liver function tests, platelet count, coagulation parameters. Fetal: Ultrasound for neural tube defects (α-fetoprotein), fetal echocardiogram, growth scans. Neurodevelopmental follow-up recommended postpartum. |
| Fertility Effects | Valproate may cause ovulatory dysfunction and polycystic ovary syndrome (PCOS)-like changes in women, leading to decreased fertility. Menstrual irregularities have been reported. Discontinuation may restore fertility. |
| Clinical Pearls | VEETIDS '125' likely refers to a 125 mg formulation of a drug (possibly a misprint for 'Vectids' or 'Veetids' which is penicillin V potassium). For penicillin V potassium, use in streptococcal pharyngitis to prevent rheumatic fever; administer on an empty stomach for optimal absorption; observe for hypersensitivity reactions including anaphylaxis; adjust dose in severe renal impairment (CrCl <10 mL/min). |
| Patient Advice | Take this medication exactly as prescribed, at evenly spaced intervals. · Complete the full course even if you feel better to prevent resistance. · Take on an empty stomach, 1 hour before or 2 hours after meals. · Do not take with acidic beverages (e.g., fruit juice, soda) as they may reduce absorption. · Notify your doctor immediately if you experience rash, itching, swelling, or difficulty breathing. · Report severe diarrhea, especially if watery or bloody, as it may indicate C. difficile infection. |